Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abemaciclib works in treating patients with ovarian or
endometrial cancer that has an activation of the CDK4/6 pathway and that has come back
(recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent
ovarian and endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Eli Lilly and Company National Cancer Institute (NCI)